Emergent BioSolutions faced a challenging fourth quarter with total revenues falling to $148.7 million, primarily driven by a 41% drop in Naloxone sales due to generic competition. Despite the quarterly loss, the company achieved full-year profitability with net income of $52.6 million and reduced its debt by $100 million as part of its multi-year turnaround strategy.
Total revenues for Q4 2025 decreased 24% to $148.7 million compared to $194.7 million in Q4 2024.
Naloxone product sales fell 41% due to increased generic competition impacting price and unit sales.
The company made a voluntary debt payment of $100 million toward its Term Loan Principal during the year.
Full-year 2025 results showed a significant turnaround with net income of $52.6 million compared to a $190.6 million loss in 2024.
For the full year 2026, Emergent expects total revenues between $720 million and $760 million, with a focus on international expansion and operational efficiency.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance